Top Mirtazapine Brands to Consider for Quality Sleep Solutions

Mirtazapine, an antidepressant, is widely prescribed for its effectiveness in treating depression and certain anxiety disorders. Several reputable pharmaceutical brands offer high-quality mirtazapine, ensuring consistent efficacy and patient satisfaction. Among the top names are Teva Pharmaceuticals, Sun Pharma, and Aurobindo, each known for their rigorous quality controls and global distribution networks. For more information on these brands and their alternatives, explore the detailed list below.

Illustration of mirtazapine

Best brands of mirtazapine in 2025

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. is a leading producer of mirtazapine, contributing significantly to the global market. The company's mirtazapine products are part of a broader portfolio that has helped the global mirtazapine drug market grow at a CAGR of 6% from 2022 to 2030, with the market expected to reach USD 2.8 billion by 2030. Teva's strong presence in regions like North America, Europe, and Asia-Pacific has been instrumental in expanding the market. The company's commitment to continuous technological development and investment in the healthcare sector has enhanced its competitive edge. As one of the key players, Teva Pharmaceutical Industries Ltd. plays a crucial role in meeting the increasing demand for mirtazapine treatments. For more details on their products, visit their official website.

Mylan Pharmaceuticals

Mylan Pharmaceuticals is a leading producer of mirtazapine, having received FDA approval for its generic version of the drug in 2003. Mylan's mirtazapine tablets are available in 15 mg, 30 mg, and 45 mg strengths, and the company is known for its extensive line of generic and branded products. Mylan's strong presence in the market is supported by its sophisticated healthcare system and continuous technological advancements. The global mirtazapine market, dominated by North America where Mylan operates, is expected to grow at a CAGR of 5.50% from 2024 to 2031. Mylan's contribution to the market is significant, with North America holding over 40% of the global revenue.

Sandoz

Sandoz is a prominent producer of mirtazapine, a tetracyclic antidepressant, known for its high-quality formulations. Sandoz B.V. received authorization for mirtazapine 15, 30, and 45 mg orodispersible tablets in the Netherlands on July 23, 2007, highlighting their commitment to meeting stringent regulatory standards. The company ensures that their mirtazapine products adhere to both USP and Ph.Eur. specifications, with additional requirements for residual solvents. Sandoz is part of the global mirtazapine market, which is expected to grow at a CAGR of 5.5% from 2024 to 2031, with North America holding over 40% of the global revenue. Their products are widely recognized for their efficacy in treating major depressive episodes. For more insights on the global mirtazapine market.

Aurobindo Pharma

Aurobindo Pharma is recognized as a leading producer of mirtazapine, a medication used primarily as an antidepressant and also administered in cats to stimulate appetite. In 2020, the company issued a recall due to mislabeled bottles that could contain 15-mg tablets instead of the labeled 7.5 mg, highlighting the importance of quality control. Aurobindo Pharma's production capacity includes a wide range of pharmaceuticals, with mirtazapine being one of the key products, manufactured in quantities such as 2.00 tons as per their production data. The company's commitment to pharmaceutical manufacturing is evident from its expansion plans and rigorous quality assessments. Despite the recall, Aurobindo Pharma remains a significant player in the global mirtazapine market.

Actavis

Actavis is a notable producer of mirtazapine, although specific data on their market share or production volume for this drug is not provided in the sources. However, the global mirtazapine market, which includes producers like Actavis, is expected to grow at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031, driven by factors such as an increasing geriatric population and rising prevalence of depression. North America, where Actavis operates, holds a significant market share, with over 40% of the global revenue in 2024. The market size for mirtazapine was estimated at USD 469.5 million in 2024, with North America growing at a CAGR of 3.7% during the forecast period. Actavis, as part of the broader pharmaceutical industry, contributes to the availability and distribution of mirtazapine. For more information, visit Actavis' official website.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a prominent producer of mirtazapine tablets, known for its robust presence in the global generics market. In FY24, the company saw a 13% year-over-year growth in global generics revenues, driven by increased volumes and new product launches, including several in the U.S. market. Dr. Reddy's has a significant footprint in regions such as North America, Europe, and India, with 19.9% of its revenues coming from the Indian market in FY23. The company has filed numerous Abbreviated New Drug Applications (ANDAs) with the USFDA, with 86 generic filings pending as of March 31, 2024. This commitment to innovation and regulatory compliance solidifies Dr. Reddy's position as a reliable producer of mirtazapine tablets.

Apotex

Apotex Inc., a prominent pharmaceutical company, has been a significant player in the production of mirtazapine, particularly noted for its dominance in the selegiline market. In 2007, Apotex's market share for generic selegiline increased from 41% to 83% due to a shortage, highlighting its capacity to meet market demands. Although the company filled 10,500 fewer prescriptions than projected during the shortage, it still maintained a strong market presence. Apotex's ability to consolidate supply and adapt to market changes underscores its position as a reliable producer of essential medications like mirtazapine. The company's performance is a testament to its operational efficiency and market resilience.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries is a leading producer of mirtazapine, contributing significantly to the global market growth expected at a CAGR of 5% from 2021 to 2028. The company's mirtazapine tablets are widely used for treating depression, insomnia, obsessive-compulsive disorder, and anxiety disorders by balancing neurotransmitters in the brain. As one of the major players, Sun Pharmaceutical Industries benefits from the increasing geriatric population and rising awareness of mental health treatments. The company's products are available in various strengths, including 15mg, 30mg, and 45mg tablets, catering to diverse patient needs. Sun Pharmaceutical Industries' strong presence in the market is supported by its well-developed healthcare sector and continuous technological advancements.

Lupin Pharmaceuticals

Lupin Pharmaceuticals is a leading producer of mirtazapine tablets, known for its significant market presence and quality products. As of 2024, Lupin is the third-largest pharmaceutical company in the U.S. by filled prescriptions, holding a 5.2% market share in generic scripts. In the Indian pharmaceutical market, Lupin had a coverage of over 76% as of the financial year 2020. The company is particularly strong in the chronic segment, with 59.8% of its total revenue coming from this area. Lupin's diverse product portfolio and robust market position make it a key player in the global mirtazapine tablets market. For more information on their business review, you can visit their official website.

Par Pharmaceutical

Par Pharmaceutical is a notable producer of mirtazapine, a tetracyclic antidepressant used to treat major depressive disorder, anxiety disorders, and other mental health conditions. The global mirtazapine market, which includes Par Pharmaceutical's offerings, was valued at USD 1.6 billion in 2022 and is expected to grow at a CAGR of 6% until 2030, reaching USD 2.8 billion. Par Pharmaceutical's mirtazapine products are available in various strengths, including 15mg, 30mg, and 45mg tablets, catering to different patient needs. The company's commitment to quality and adherence to stringent regulatory standards, such as those set by the USP and Ph.Eur., ensures the reliability and efficacy of their mirtazapine formulations. With a strong presence in regions like North America, Par Pharmaceutical contributes significantly to the global accessibility of mirtazapine.